Leora Horn

Leora Horn

UNVERIFIED PROFILE

Are you Leora Horn?   Register this Author

Register author
Leora Horn

Leora Horn

Publications by authors named "Leora Horn"

Are you Leora Horn?   Register this Author

100Publications

6358Reads

26Profile Views

Quantitative Assessment of Learning Behaviors for Oncology Providers.

J Cancer Educ 2019 Aug 3. Epub 2019 Aug 3.

Vanderbilt University Medical Center, 1211 Medical Center Drive, Nashville, TN, 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13187-019-01593-4DOI Listing
August 2019

Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer.

J Thorac Oncol 2019 Aug 22. Epub 2019 Aug 22.

Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, 1211 Medical Center Drive, Nashville, TN 37232; Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, Nashville, TN 37232.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.08.003DOI Listing
August 2019

Palliative Care Referrals for Advanced Non-small-cell Lung Cancer (NSCLC): Patient and Provider Attitudes and Practices.

Clin Lung Cancer 2019 May 20;20(3):e291-e298. Epub 2019 Feb 20.

Vanderbilt University Medical Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.002DOI Listing
May 2019

Low Provider Knowledge Is Associated With Less Evidence-Based Lung Cancer Screening.

J Natl Compr Canc Netw 2019 Apr;17(4):339-346

aGeriatric Research, Education and Clinical Center, Veterans Health Administration - Tennessee Valley Healthcare System, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7101DOI Listing
April 2019

Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Report of Two Cases.

J Thorac Oncol 2019 Mar 10;14(3):e45-e48. Epub 2018 Dec 10.

Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382512PMC
March 2019

Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer. Reply.

N Engl J Med 2019 02;380(9):889-890

Georgetown University, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1900123DOI Listing
February 2019

Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:e187-e197. Epub 2019 May 17.

4 Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_237821DOI Listing
January 2019

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

N Engl J Med 2018 12 25;379(23):2220-2229. Epub 2018 Sep 25.

From Vanderbilt University Medical Center (L. Horn) and Sarah Cannon Research Institute-Tennessee Oncology (M.L.J.), Nashville; Mayo Clinic, Rochester, MN (A.S.M.); Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Otwock (A. Szczęsna), and Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie w Warszawie, Warsaw (M.K.) - both in Poland; Thomayerova Nemocnice, Pneumologická Klinika 1.LF UK, Prague, Czech Republic (L. Havel); the Department of Respiratory and Critical Care Medicine (M.J.H.) and the 2nd Department of Respiratory and Critical Care Medicine (F.H.), Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology-Sozialmedizinisches Zentrum Baumgartner Höhe, Otto-Wagner-Spital, Vienna; Semmelweis Egyetem ÁOK, Pulmonológiai Klinika, Budapest, Hungary (G.L.); the Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo (M.N.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany (M.R.); State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong (T.M.), and F. Hoffmann-La Roche, Shanghai (J.L.) - both in China; Genentech, South San Francisco, CA (S.L., D.S.S., B.D., A.L.-C., F.K., W.L., A. Sandler); and Georgetown University, Washington DC (S.V.L.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1809064
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1809064DOI Listing
December 2018

Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.

Future Oncol 2018 Aug 6;14(18):1781-1787. Epub 2018 Mar 6.

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0619DOI Listing
August 2018

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

J Clin Oncol 2018 06 23;36(17):1675-1684. Epub 2018 Mar 23.

Scott Gettinger, Yale Cancer Center, New Haven, CT; Leora Horn, Vanderbilt University Medical Center; David Spigel, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; David Jackman, Dana-Farber Cancer Institute; Rebecca Heist and Lecia V. Sequist, Massachusetts General Hospital, Boston, MA; Scott Antonia, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Matthew Hellmann, Memorial Sloan-Kettering Cancer Center, New York, NY; John Powderly, Carolina BioOncology Institute, Huntersville, NC; David C. Smith, University of Michigan, Ann Arbor, MI; Philip Leming, The Christ Hospital Cancer Center, Cincinnati, OH; William J. Geese, Dennis Yoon, and Ang Li, Bristol-Myers Squibb, Princeton, NJ; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.77.0412
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.77.0412DOI Listing
June 2018

Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction.

J Immunother Cancer 2016 18;4:60. Epub 2016 Oct 18.

Departments of Medicine, Vanderbilt Ingram Cancer Center, 777 PRB, 2220 Pierce Ave., Nashville, TN 37232 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0166-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067899PMC
February 2018

Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.

J Thorac Oncol 2018 01 23;13(1):112-123. Epub 2017 Sep 23.

Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.09.1951DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827950PMC
January 2018

Before or After: Evolving Neoadjuvant Approaches to Locally Advanced Non-Small Cell Lung Cancer.

Front Oncol 2018 23;8. Epub 2018 Jan 23.

Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2018.00005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787144PMC
January 2018

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

J Clin Oncol 2017 Dec 12;35(35):3924-3933. Epub 2017 Oct 12.

Leora Horn, Vanderbilt-Ingram Cancer Center; David R. Spigel, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Everett E. Vokes, University of Chicago, Chicago, IL; Esther Holgado, Hospital De Madrid, Norte Sanchinarro, Madrid; Enriqueta Felip, Hospital Universitari Vall d'Hebron, Barcelona; Luis Paz-Ares, Hospital Universitario Virgen Del Rocio, Seville, Spain; Neal Ready, Duke University Medical Center, Durham, NC; Martin Steins, Thoraxklinik-Heidelberg gGmbH, Heidelberg; Martin Kohlhäeufl, Robert-Bosch-Krankenhaus, Stuttgart; Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Wilfried E.E. Eberhardt, University Hospital and Ruhrlandclinic, University of Duisburg-Essen, Essen, Germany; Elena Poddubskaya, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Adam Pluzanski, Centrum Onkologii-Instytut Im. Marii Sklodowskiej-Curie, Warsaw, Poland; Karen L. Reckamp, City of Hope, Duarte, CA; Marco A. Burgio and Lucio Crinò, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Scientifico Romagnolo Per lo Studio e la Cura dei Tumori, Meldola, Italy; David Waterhouse, Oncology Hematology Care (OHC)/US Oncology, Cincinnati, OH; Fabrice Barlesi, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Marseille; Jérôme Fayette, Léon Bérard, Lyon, France; Scott Antonia, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Oscar Arrieta, Instituto Nacional De Cancerologia, Mexico City, Mexico; Naiyer Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; William J. Geese, Ang Li, Anne Blackwood-Chirchir, and Diane Healey, Bristol-Myers Squibb, Princeton, NJ; and Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.3062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075826PMC
December 2017

Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.

J Clin Oncol 2017 Aug 26;35(24):2790-2797. Epub 2017 May 26.

Rebecca Suk Heist and Aditya Bardia, Massachusetts General Hospital Cancer Center; Rebecca Suk Heist and Aditya Bardia, Harvard Medical School, Boston, MA; Michael J. Guarino and Gregory Masters, Helen F. Graham Cancer Center & Research Institute, Newark, DE; W. Thomas Purcell, Wells A. Messersmith, and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Leora Horn and Jordan Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN; Ronald J. Scheff and Allyson J. Ocean, Weill Cornell Medicine, New York, NY; and Serengulam V. Govindan, Pius Maliakal, Boyd Mudenda, William A. Wegener, Robert M. Sharkey, and David M. Goldenberg, Immunomedics, Morris Plains, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.1894DOI Listing
August 2017

Plasma genotyping in patients with non-small-cell lung cancer: simplifying or confusing the diagnosis?

Lung Cancer Manag 2017 Jul 19;6(1):29-37. Epub 2017 May 19.

2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/lmt-2016-0019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310325PMC
July 2017

Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives.

Onco Targets Ther 2017 24;10:3697-3708. Epub 2017 Jul 24.

Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S97903DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533488PMC
July 2017

Immunotherapy in Lung Cancer.

Cancer Treat Res 2016;170:203-23

Division of Hematology/Oncology, Vanderbilt Ingram Cancer Center, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN, 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-40389-2_10DOI Listing
June 2017

A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases.

J Neurooncol 2017 Jun 9;133(2):435-442. Epub 2017 May 9.

Department of Radiation Oncology, University of Arkansas for Medical Sciences, 4301 W. Markham, Little Rock, AR, 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-017-2455-3DOI Listing
June 2017

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

N Engl J Med 2017 06;376(25):2415-2426

From the Ohio State University Comprehensive Cancer Center, Columbus (D.P.C.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.), and Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) - both in Germany; Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas and Universidad Complutense, Madrid (L.P.-A., J.C.J.), Vall d'Hebron University Hospital, Barcelona (E.F.), and Hospital Universitario Insular de Gran Canaria, Las Palmas (D.R.-A.) - all in Spain; H. Lee Moffitt Cancer Center, Tampa, FL (B.C.); Vanderbilt University Medical Center, Nashville (L. Horn); Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (M.M.H.), and University of Groningen, Universitair Medisch Centrum Groningen, Groningen (T.J.N.H.) - both in the Netherlands; Prof. Dr. Ion Chiricuta Institute of Oncology and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.); Baptist Health Lexington, Lexington, KY (F.B.); Duke University, Durham, NC (N.R.); Lehigh Valley Health Network, Allentown (S.N.), Fox Chase Cancer Center, Philadelphia (H.B.), and University of Pittsburgh Medical Center Cancer Center, Pittsburgh (L.C.V., M.A.S.) - all in Pennsylvania; Juravinski Cancer Centre, Hamilton, ON, Canada (R.J.); Oncology Department, Lausanne University Hospital, Lausanne, Switzerland (S.P.); Santa Maria Hospital, Terni, Italy (E.M.); Hollings Cancer Center, Charleston, SC (J.M.W.); Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.); Klinika Pneumologie a Hrudní Chirurgie, Nemocnice Na Bulovce, Prague, Czech Republic (L. Havel, J.K.); and Bristol-Myers Squibb, Princeton, NJ (H.C., W.J.G., P.B., A.C.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1613493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487310PMC
June 2017

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer.

J Thorac Oncol 2017 04 23;12(4):612-623. Epub 2016 Dec 23.

Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864163360
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2016.12.014DOI Listing
April 2017

Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions.

J Natl Cancer Inst 2017 01 28;109(7). Epub 2017 Jan 28.

Affiliations of authors: Department of Internal Medicine, Hematology/Oncology, Harold C. Simmons Comprehensive Cancer Center (LP, AM, JDM, JS), Department of Biostatistics (CA, AG), Hamon Center for Therapeutic Oncology Research (JDM, AFG), Department of Pharmacology (JDM), Department of Pathology (AFG), UT Southwestern, Dallas, TX; Department of Hematology/Oncology, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Nashville, TN (LH, DM); Parkland Memorial Hospital, Dallas, TX (JC).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw295DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279285PMC
January 2017

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

J Clin Oncol 2016 11;34(31):3740-3748

Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, Grosshansdorf; Michael Thomas, Translational Lung Research Center Heidelberg, Thoraxklinik im Universitätsklinikum Heidelberg, Heidelberg, Germany; Alexander Luft, Leningrad Regional Clinical Hospital, Leningrad, Russia; Aleksandra Szczesna, Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy w Otwocku, Otwocku, Poland; Libor Havel, Hospital Na Bulovce, Prague, Czech Republic; Sang-We Kim, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea; Wallace Akerley, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Maria Catherine Pietanza, Memorial Sloan Kettering Cancer Center, New York, NY; Kathryn Gold, University of Texas MD Anderson Cancer Center, Houston, TX; Leora Horn, Vanderbilt-Ingram Cancer Center; David Spigel, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Anne Pieters, Teresa Kong Sanchez, and Justin Fairchild, Bristol-Myers Squibb, Princeton, NJ; Yi-long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong, People's Republic of China; Christoph Zielinski, Medical University of Vienna, Vienna, Austria; Enriqueta Felip, Vall d'Hebron University Hospital, Barcelona, Spain; Joachim Aerts, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Kazuhiko Nakagawa, Kinki University Hospital, Osaka, Japan; and Paul Lorigan, the Christie NHS Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.67.6601
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.67.6601DOI Listing
November 2016

Rheumatologic skills development: what are the needs of internal medicine residents?

Clin Rheumatol 2016 Aug 23;35(8):2109-2115. Epub 2015 Dec 23.

Department of Medicine, Vanderbilt University School of Medicine, 1161 21st Avenue So. T3113 MCN, Nashville, TN, 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-015-3150-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919226PMC
August 2016

The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.

Oncologist 2016 08 27;21(8):910-21. Epub 2016 Jun 27.

Sarah Cannon Research Institute, Nashville, Tennessee, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0523DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978554PMC
August 2016

Immune Checkpoint Inhibition in Lung Cancer: The Good, the Bad, and the Ugly.

Oncology (Williston Park) 2016 08;30(8):722-3

View Article

Download full-text PDF

Source
August 2016

NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

J Natl Compr Canc Netw 2016 07;14(7):825-36

From The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Huntsman Cancer Institute at the University of Utah; UC San Diego Moores Cancer Center; Fox Chase Cancer Center; University of Colorado Cancer Center; Roswell Park Cancer Institute; Dana-Farber/Brigham and Women's Cancer Center; Duke Cancer Institute; Moffitt Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Vanderbilt-Ingram Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Fred & Pamela Buffett Cancer Center; Massachusetts General Hospital Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Michigan Comprehensive Cancer Center; Stanford Cancer Institute; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; City of Hope Comprehensive Cancer Center; Memorial Sloan Kettering Cancer Center; Mayo Clinic Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0087DOI Listing
July 2016

Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.

Oncologist 2016 06 6;21(6):755-61. Epub 2016 Apr 6.

Department of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0396DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912362PMC
June 2016

Targeting PD-L1 for non-small-cell lung cancer.

Immunotherapy 2016 06;8(6):747-58

Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Department of Medicine, Division of Hematology/Oncology, TN, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2016-0012
Publisher Site
http://dx.doi.org/10.2217/imt-2016-0012DOI Listing
June 2016

Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer.

J Natl Compr Canc Netw 2016 05;14(5 Suppl):672-4

Presented by Rogerio A. Lilenbaum, MD, Yale Cancer Center/Smilow Cancer Hospital, New Haven, Connecticut, and Leora A. Horn, MD, MSc, FRCPC, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0189DOI Listing
May 2016

Medical education: perils and progress in educating and assessing a new generation of learners.

Am Soc Clin Oncol Educ Book 2015 :33-9

From the Vanderbilt University School of Medicine, Nashville, TN; University of California Davis School of Medicine, Sacramento, CA; Vanderbilt University School of Medicine, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.33DOI Listing
February 2016

Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.

Lung Cancer 2016 Feb 10;92:29-34. Epub 2015 Nov 10.

Department of Medicine/Division of Hematology-Oncology, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN 37232, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.11.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874190PMC
February 2016

Faculty Development on Clinical Teaching Skills: An Effective Model for the Busy Clinician.

J Med Educ Curric Dev 2016 Jan-Dec;3. Epub 2016 Jan 4.

Division of Cardiology, Vanderbilt University School of Medicine, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/JMECD.S40798DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757630PMC
January 2016

Making the Grade: The Impact of Low-Grade Toxicities on Patient Preference for Treatment With Novel Agents.

J Natl Compr Canc Netw 2015 Dec;13(12):1490-5

From the Division of Hematology and Oncology, Vanderbilt University Medical Center; Division of Quantitative Sciences, Vanderbilt University Medical Center; and Vanderbilt University School of Medicine, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0177DOI Listing
December 2015

Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress.

Curr Treat Options Oncol 2015 Oct;16(10):51

Vanderbilt Ingram Cancer Center, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN, 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-015-0365-1DOI Listing
October 2015

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

N Engl J Med 2015 Oct 27;373(17):1627-39. Epub 2015 Sep 27.

From the Fox Chase Cancer Center, Philadelphia (H.B.); Hospital Universitario Virgen del Rocio, Seville (L.P.-A.), Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona (E.F.), and Hospital de Madrid, Norte Sanchinarro, Madrid (E.H.) - all in Spain; Vanderbilt-Ingram Cancer Center (L.H.), and Sarah Cannon Research Institute and Tennessee Oncology (D.R.S.) - both in Nashville; Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) and Robert-Bosch-Krankenhaus Stuttgart, Gerlingen (M.K.) - both in Germany; Duke University Medical Center, Durham, NC (N.E.R.); University of Washington, Seattle (L.Q.C.); University of Chicago Medicine and Biological Sciences, Chicago (E.E.V.); Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille (F.B.), Centre Léon Bérard, Lyon (J.F.), and Centre Hospitalier Universitaire de Rennes, Rennes (H.L.) - all in France; Instituto Nacional de Cancerologia, Mexico City (O.A.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Forlì-Cesena (M.A.B.), and Ospedale di Perugia, Perugia (L.C.) - both in Italy; N.N. Blokhin Russian Cancer Research Center, Moscow (E.P.); University of Texas Southwestern Medical Center, Dallas (D.E.G.); Yale Comprehensive Cancer Center, New Haven, CT (S.N.G.); Memorial Sloan Kettering Cancer Center, New York (C.M.R., N.R.); University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (S.J.A.); Bristol-Myers Squibb, Princeton, NJ (C.D., C.T.H., F.G.F.); and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.R.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1507643DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705936PMC
October 2015

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2015 Jun 20;33(18):2004-12. Epub 2015 Apr 20.

Scott N. Gettinger and Mario Sznol, Yale Cancer Center, New Haven, CT; Leora Horn, David P. Carbone, and Jeffrey A. Sosman, Vanderbilt University Medical Center; David R. Spigel, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Leena Gandhi, David M. Jackman, and F. Stephen Hodi, Dana-Farber Cancer Institute; Rebecca S. Heist and Lecia V. Sequist, Massachusetts General Hospital Cancer Center; David F. McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Scott J. Antonia and Mary C. Pinder-Schenck, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Naiyer A. Rizvi, Richard D. Carvajal, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; David C. Smith, University of Michigan, Ann Arbor, MI; Philip Leming, Christ Hospital Cancer Center, Cincinnati, OH; Suzanne L. Topalian, Drew M. Pardoll, and Julie R. Brahmer, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; and Vindira Sankar, Christoph M. Ahlers, Mark Salvati, Jon M. Wigginton, Georgia D. Kollia, and Ashok K. Gupta, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/04/15/JCO.2014.58
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.3708
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.3708DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672027PMC
June 2015

Non-Small Cell Lung Cancer, Version 6.2015.

J Natl Compr Canc Netw 2015 May;13(5):515-24

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Washington/Seattle Cancer Care Alliance; Huntsman Cancer Institute at the University of Utah; UC San Diego Moores Cancer Center; Fox Chase Cancer Center; University of Colorado Cancer Center; Roswell Park Cancer Institute; Dana-Farber/Brigham and Women's Cancer Center; Duke Cancer Institute; Moffitt Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; City of Hope Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Fred & Pamela Buffett Cancer Center; Massachusetts General Hospital Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Michigan Comprehensive Cancer Center; Stanford Cancer Institute; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Mayo Clinic Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0071DOI Listing
May 2015

Targeted/emerging therapies for metastatic non-small cell lung cancer.

Authors:
Leora Horn

J Natl Compr Canc Netw 2015 May;13(5 Suppl):676-8

Presented by Leora Horn, MD, MSc, Associate Professor of Medicine, Department of Hematology Oncology; Clinical Director, Thoracic Oncology Research Program; and Assistant Director, Educator Development Program, Vanderbilt University, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0201DOI Listing
May 2015

Are We Making Progress in Lung Cancer Using Progression-Free Survival as a Surrogate End Point?

JAMA Oncol 2015 May;1(2):202-3

Center for Quantitative Sciences, Vanderbilt University, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.0407DOI Listing
May 2015

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

N Engl J Med 2015 Apr;372(18):1689-99

From the Lowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston (P.A.J.); National Taiwan University and National Taiwan University Hospital (J.C.-H.Y.) and Cheng Kung University Hospital (W.-C.S.) - both in Taipei, Taiwan; Seoul National University Hospital (D.-W.K.), Samsung Medical Center (M.-J.A.), Asan Medical Center (S.-W.K.), and Yonsei Cancer Center, Yonsei University Health System (J.-H.K.) - all in Seoul, South Korea; Institut Gustave Roussy, Villejuif, France (D.P.); National Cancer Center Hospital, Tokyo (Y.O.); Winship Cancer Institute of Emory University, Atlanta (S.S.R.); Vanderbilt Ingram Cancer Center, Nashville (L.H.); Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC (D.H.); Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona (E.F.); and AstraZeneca, Macclesfield (P.F., M.C., K.H.B., P.A.D., S.G.), and University of Manchester, Christie Hospital, Manchester (M.R.) - both in the United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1411817DOI Listing
April 2015

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.

J Thorac Oncol 2015 Mar;10(3):431-7

*Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, †Department of Epidemiology and Biostatistics, ‡Department of Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY; §Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA; ‖Department of Medicine, Vanderbilt Ingram Cancer Center, Franklin, TN; and ¶Lowe center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479120PMC
March 2015

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

J Thorac Oncol 2015 Jan;10(1 Suppl 1):S1-63

*Department of Medical Oncology, Washington University School of Medicine, Saint Louis, Missouri; Departments of †Medical Oncology and ‡Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts; §Department of Medical Oncology, University of Colorado School of Medicine and University of Colorado Cancer Center, Aurora, Colorado; ‖UCLA Santa Monica Hematology Oncology, Santa Monica, California; ¶Division of Hematology-Oncology, Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas; #Department of Medical Oncology, Yale School of Medicine and Cancer Center, New Haven, Connecticut; **Massachusetts General Hospital Cancer Center, Boston, Massachusetts; ††Department of Oncology, The University of Chicago Medicine, Chicago, Illinois; ‡‡Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee; §§Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia; ‖‖Memorial Sloan-Kettering Cancer Center, New York, New York; ¶¶Division of Hematology-Oncology, Medical University of South Carolina, Charleston, South Carolina; ##Sarah Cannon Research Institute, Nashville, Tennessee; ***The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; †††Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas; and ‡‡‡Division of Medical Oncology, University of Colorado Denver School of Medicine, Denver, Colorado.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000405DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346098PMC
January 2015

Immune checkpoint inhibitors in NSCLC.

Curr Treat Options Oncol 2014 Dec;15(4):658-69

Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN, 37232, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-014-0305-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216599PMC
December 2014

Beyond histology: translating tumor genotypes into clinically effective targeted therapies.

Clin Cancer Res 2014 May 5;20(9):2264-75. Epub 2014 Mar 5.

Authors' Affiliations: Departments of Cancer Biology, Medicine, Biomedical Informatics, and Pathology, Microbiology, and Immunology; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1591DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008689PMC
May 2014

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

Cell Rep 2014 May 9;7(4):999-1008. Epub 2014 May 9.

Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06510, USA; Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA; Department of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT 06510, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2014.04.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074596PMC
May 2014

Advances in the treatment of non-small cell lung cancer.

Authors:
Leora Horn

J Natl Compr Canc Netw 2014 May;12(5 Suppl):764-7

Presented by Leora Horn, MD, MSc, Associate Professor of Medicine, Department of Hematology Oncology; Clinical Director, Thoracic Oncology Research Program, Vanderbilt University, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0185DOI Listing
May 2014

Satisfaction with work-life balance and the career and retirement plans of US oncologists.

J Clin Oncol 2014 Apr 10;32(11):1127-35. Epub 2014 Mar 10.

Tait D. Shanafelt, Daniel Satele, and Jeff Sloan, Mayo Clinic, Rochester, MN; Marilyn Raymond, William Benton Clark, and Amy E. Hanley, American Society of Clinical Oncology, Alexandria, VA; Michael Kosty, Scripps Clinic, La Jolla; Helen Chew, University of California at Davis, Davis, CA; Leora Horn, Vanderbilt University Medical Center, Nashville, TN; John Pippen, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX; Quyen Chu, Louisiana State University Health Sciences Center, Shreveport, LA; and William J. Gradishar, Northwestern University, Evanston, IL.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.53.4560
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.53.4560DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876331PMC
April 2014

Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer.

J Thorac Oncol 2014 Apr;9(4):559-62

*Department of Internal Medicine, Meharry Medical College, Nashville, Tennessee; †Department of Biostatistics, Center for Quantitative Science, Vanderbilt University Medical Center, Nashville, Tennessee; ‡South Carolina Oncology Associates, Columbia, South Carolina; §Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, OHSU Knight Cancer Institute, Portland, Oregon; ‖Department of Medicine, Division of Medical Oncology, The Ohio State University Medical Center, Arthur G. James Cancer Hospital, Columbus, Ohio; ¶Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas; and #Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000079DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990869PMC
April 2014

Patient enrollment onto clinical trials: the role of physician knowledge.

J Cancer Educ 2014 Mar;29(1):74-9

Department of Urologic Surgery, Vanderbilt University Medical Center, A - 1302 Medical Center North, Nashville, TN, 37232-2765, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13187-013-0548-zDOI Listing
March 2014

Burnout and career satisfaction among US oncologists.

J Clin Oncol 2014 Mar 27;32(7):678-86. Epub 2014 Jan 27.

Tait D. Shanafelt, Daniel Satele, Jeff Sloan, Mayo Clinic, Rochester, MN; William J. Gradishar, Northwestern University, Evanston, IL; Michael Kosty, Scripps Clinic, La Jolla; Helen Chew, University of California Davis, Davis, CA; Leora Horn, Vanderbilt University Medical Center, Nashville, TN; Ben Clark, Amy E. Hanley, Marilyn Raymond, American Society of Clinical Oncology, Alexandria, VA; Quyen Chu, Louisiana State University Health Sciences Center, Shreveport, LA; and John Pippen, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.8480DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3927737PMC
March 2014

Reducing lung cancer mortality: 2014 update.

Semin Oncol 2014 Feb 12;41(1):3-4. Epub 2013 Dec 12.

Director, James Thoracic Center James Cancer Center The Ohio State University Medical Center Columbus, OH Guest Editors.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00937754130021
Publisher Site
http://dx.doi.org/10.1053/j.seminoncol.2013.12.004DOI Listing
February 2014

A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.

J Natl Compr Canc Netw 2014 Jan;12(1):6-11; quiz 11

From the Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4151469PMC
http://dx.doi.org/10.6004/jnccn.2014.0002DOI Listing
January 2014

Clinician perceptions of care difficulty, quality of life, and symptom reports for lung cancer patients: an analysis from the Symptom Outcomes and Practice patterns (SOAPP) study.

J Thorac Oncol 2013 Dec;8(12):1474-83

*Harold C. Simmons Cancer Center, Departments of Psychiatry and Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas; †Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts; ‡Harold C. Simmons Cancer Center, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; §Department of Medical Oncology, Vanderbilt University, Nashville, Tennessee; ‖Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois; ¶VA New Jersey Health Care System, East Orange, New Jersey, Rutgers - New Jersey Medical School, Newark, New Jersey; and #Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153012
Publisher Site
http://dx.doi.org/10.1097/01.JTO.0000437501.83763.5dDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3936653PMC
December 2013

Targeting angiogenesis in advanced non-small cell lung cancer.

J Natl Compr Canc Netw 2013 Oct;11(10):1235-47

From Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628716PMC
http://dx.doi.org/10.6004/jnccn.2013.0146DOI Listing
October 2013

Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms.

AJR Am J Roentgenol 2013 Mar;200(3):475-83

Department of Radiology and Radiological Science, Vanderbilt University School of Medicine, 1161 21st Ave S, CCC-1121 MCN, Nashville, TN 37232-2675, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.12.9049DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652983PMC
March 2013